These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28380437)

  • 21. O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma.
    Yeager ND; Dolan ME; Gastier JM; Gross TG; Delaney S; Frick J; Ruymann FB; Ewesuedo R
    J Pediatr Hematol Oncol; 2003 Dec; 25(12):941-7. PubMed ID: 14663276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular biology of rhabdomyosarcoma.
    Gallego Melcón S; Sánchez de Toledo Codina J
    Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.
    Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG
    Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
    Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
    Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
    Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
    Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Takahira T; Takahashi Y; Tajiri T; Taguchi T; Suita S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1097-103. PubMed ID: 18386058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
    Treetipsatit J; Kittikowit W; Zielenska M; Chaipipat M; Thorner PS; Shuangshoti S
    Pediatr Dev Pathol; 2009; 12(5):383-9. PubMed ID: 19175284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
    Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
    Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas.
    Schneider G; Bowser MJ; Shin DM; Barr FG; Ratajczak MZ
    Int J Oncol; 2014 Jan; 44(1):295-300. PubMed ID: 24173021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel t(2;20)(q35;p12) in embryonal rhabdomyosarcoma.
    Ho RH; Johnson J; Dev VG; Whitlock JA
    Cancer Genet Cytogenet; 2004 May; 151(1):73-7. PubMed ID: 15120913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of FOXO1 break-apart status by fluorescence in situ hybridization in atypical alveolar rhabdomyosarcoma.
    Fu L; Jin Y; Jia C; Zhang J; Tai J; Li H; Chen F; Shi J; Guo Y; Ni X; He L
    Sci China Life Sci; 2017 Jul; 60(7):721-728. PubMed ID: 28646473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.
    Wachtel M; Dettling M; Koscielniak E; Stegmaier S; Treuner J; Simon-Klingenstein K; Bühlmann P; Niggli FK; Schäfer BW
    Cancer Res; 2004 Aug; 64(16):5539-45. PubMed ID: 15313887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.
    Rudzinski ER; Anderson JR; Lyden ER; Bridge JA; Barr FG; Gastier-Foster JM; Bachmeyer K; Skapek SX; Hawkins DS; Teot LA; Parham DM
    Am J Surg Pathol; 2014 May; 38(5):654-9. PubMed ID: 24618610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.